Preparation and Characterization of Avenin-Enriched Oat Protein by Chill Precipitation for Feeding Trials in Celiac Disease

Greg Tanner1,†, Angéla Juhász2,†, Christakis George Florides3, Mitchell Nye-Wood2, Frank Békés4, Michelle L. Colgrave2, Amy K. Russell5,6, Melinda Y. Hardy5,6 and Jason A. Tye-Din5,6,7,8

1 School of Biosciences, University of Melbourne, Melbourne, VIC, Australia, 2 School of Science, Edith Cowan University, Joondalup, WA, Australia, 3 School of Veterinary and Life Sciences, Murdoch University, Murdoch, WA, Australia, 4 FBFD PTY LTD, Sydney, NSW, Australia, 5 Immunology Division, The Walter and Eliza Hall Institute, Melbourne, VIC, Australia, 6 Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia, 7 Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, VIC, Australia, 8 Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC, Australia

The safety of oats for people with celiac disease remains unresolved. While oats have attractive nutritional properties that can improve the quality and palatability of the restrictive, low fiber gluten-free diet, rigorous feeding studies to address their safety in celiac disease are needed. Assessing the oat prolamin proteins (avenins) in isolation and controlling for gluten contamination and other oat components such as fiber that can cause non-specific effects and symptoms is crucial. Further, the avenin should contain all reported immunogenic T cell epitopes, and be deliverable at a dose that enables biological responses to be correlated with clinical effects. To date, isolation of a purified food-grade avenin in sufficient quantities for feeding studies has not been feasible. Here, we report a new gluten isolation technique that enabled 2 kg of avenin to be extracted from 400 kg of wheat-free oats under rigorous gluten-free and food grade conditions. The extract consisted of 85% protein of which 96% of the protein was avenin. The concentration of starch (1.8% dry weight), β-glucan (0.2% dry weight), and free sugars (1.8% dry weight) were all low in the final avenin preparation. Other sugars including oligosaccharides, small fructans, and other complex sugars were also low at 2.8% dry weight. Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of the proteins in these preparations showed they consisted only of oat proteins and were uncontaminated by gluten containing cereals including wheat, barley or rye. Proteomic analysis of the avenin enriched samples detected more avenin subtypes and fewer other proteins compared to samples obtained using other extraction procedures. The identified proteins represented five main groups, four containing known immune-stimulatory avenin peptides. All five groups were identified in the 50% (v/v) ethanol extract however the group harboring the epitope DQ2.5-ave-1b was less represented. The avenin-enriched protein fractions were quantitatively collected by reversed phase HPLC and analyzed by...
INTRODUCTION

Establishing a safe gluten-free diet (GFD) for people with celiac disease (CD) is important for the health of the 1.4% of affected sufferers globally (1). CD is a chronic immune illness with features closely related to autoimmunity, and its pathogenesis is strongly linked to CD4+ T cells that are activated by dietary gluten peptides (2). Since the 1950s, after gluten was identified as the causative antigenic trigger, its sole treatment has been strict and lifelong gluten exclusion by removing wheat, barley, and rye. In this clinical context, the term gluten encompasses all of the pathogenic prolamin proteins from wheat (gliadin and glutenin), barley (hordein) and rye (secalin) that are immunotoxic in CD.

Oats contain a gluten-like prolamin protein called avenin and early food challenge studies indicated they can cause clinical relapse in some people with CD (3). More recent oat feeding studies that control for the confounding effect of wheat and barley contamination have indicated that pure oats are safe in CD although methodological limitations of these studies have been identified (4). A few clinical studies have shown mucosal inflammation (5), raised intra-epithelial lymphocytes (6, 7), or villous atrophy (8) induced by oats, suggestive of an adverse CD effect. A variety of in vitro studies have shown oat fractions can induce pro-inflammatory immune effects (9–11). Importantly, key avenin peptides that stimulate the pathogenic gluten-specific T cells in CD patients in vivo have been defined (12, 13). These peptides contain the immunodominant T cell epitopes DQ2.5-ave-1a (PYPEQEEPFP), DQ2.5-ave-1b (PYPEQEQPFP), DQ2.5-ave-1c (PYPEQEQPI), and DQ2.5-ave-2 (PYPEQEOPFP) with close sequence homology to barley T cell epitopes immunotoxic in CD such as DQ2.5-hor-3 (PIPEQPQPY) (14). The collective uncertainty of these findings regarding the true clinical safety of oats in CD has translated into different feeding recommendations; while Australia and New Zealand mandate the exclusion of oats from the GFD, most countries do not.

Oats are the sixth most significant cereal crop in the world, with production exceeding 24 million tons annually, and Avena sativa is the most important crop (15). Oats, wheat, barley and rye belong to the same Poaceae family but oats are sub-classified into the Aveneae tribe, while the other cereals belong to the Triticeae tribe. This phylogenetic relationship is exemplified by the homology between oat avenin sequences with those in α- and γ-gliadins of wheat, the B-hordeins of barley and the γ-secalins of rye. Notably, there is no homology with the 33mer peptide from wheat α-gliadin that encompasses several highly immunostimulatory T cell epitopes in CD. An important distinction is that within the Triticeae tribe, gluten protein makes up 75–80% of the protein in wheat, 45–50% in rye, and 50–55% in barley, but in the Aveneae tribe the equivalent prolamin protein (avenin) makes up only 10–15% of the protein i.e., 1% of the flour (16). This has particular relevance for feeding studies in CD. To illustrate, the consumption of 3–7 g wheat gluten daily induces typical clinical effects in most CD patients after 2 weeks (17), however the equivalent avenin prolamin dose would require the consumption of ∼300–700 g oats per day. As a standard serving size is ∼30–40 g, this is impractical and makes oat feeding studies aiming to reliably induce and assess biological effects near impossible.

A strict GFD is essential to ensure mucosal healing in CD and a failure to heal is correlated with higher morbidity and mortality (18, 19). This is an onerous, costly and restrictive treatment and its ability to induce CD remission is compromised by poor dietary adherence (20). The GFD is generally lower in dietary fiber and frequently higher in simple carbohydrates and fat (21). The introduction of oats to the GFD increases the range of foods that can be consumed, provides an excellent source of fiber and increases GFD palatability and adherence. Soluble fiber and β-glucan found in oats have been associated with a range of health benefits including reduced serum cholesterol (22, 23). Oats may support the 8–10% of CD patients who also suffer Type 1 diabetes mellitus by lowering post-prandial glycaemia and improving glycaemic control. Long-term oat consumption in CD may also improve quality of life (24).

In the face of these extremely positive nutritional attributes for oats in people with CD yet with the uncertain issue of their safety, there is a strong medical need to resolve this issue. It has become clear from trials in a separate clinical entity, non-celiac wheat sensitivity (NCWS), that properly controlled feeding studies to assess the clinical effects of gluten need to feed purified gluten, and not whole wheat (25). Wheat contains a broad mix of proteins [including gliadins, glutenins, amylase trypsin inhibitors (ATIs), and globulins] and carbohydrates. Recent controlled feeding studies indicate the fermentable carbohydrate component, fructan, is the driver of adverse gastrointestinal symptomatology in many people with NCWS (26). While oats, unlike wheat, is considered low in fermentable carbohydrates (27), it is high in fiber which could

Abbreviations: AACC, American Association of Cereal Chemists; ATIs, α-amylase/trypsin inhibitors; CD, coeliac disease; cRAP, common Repository of Advenitious Proteins; DTT, dithiothreitol; FDA, US Food and Drug Administration; GFD, gluten-free diet; HRP, horseradish peroxidase; IPA, propan-2-ol; IPA/DTT, 50% (v/v) IPA, 1% (w/v) DTT; LC-MS/MS, liquid chromatography tandem mass spectrometry; LOD, limit of detection; MALDI-TOF-MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; NCWS, non-celiac wheat sensitivity; RP-HPLC, reverse phase high pressure liquid chromatography; Urea/DDT, 8 M urea, 1% (w/v) DTT, 20 mM triethylamine-HCl (pH 6).
trigger adverse gastrointestinal symptoms such as bloating or abdominal discomfort independent of its avenin content. With remarkable foresight, researchers in 1958 reported the challenge of getting children with CD to consume enough oats to establish clinical safety, and identified the need to extract oat protein i.e., avenin to address this challenge (28). At the time, the author lamented, “The possibility of using oat protein itself was explored but although several methods of preparation were attempted, considerable difficulties were encountered.” Thus, there exists a need for purified and uncontaminated food-grade avenin in sufficient quantities for CD feeding studies. We present here a simple method capable of isolating purified, avenin-enriched protein. We demonstrate the avenin is of food-grade standard, uncontaminated by agricultural chemicals and heavy metals, and suitable for human feeding trials.

**METHODS**

**Protein Content Determination**

Protein content was determined by the method of Bradford (29).

**Proximate Composition Analysis**

All proximate analyses were completed by a National Association of Testing Authorities accredited food testing facility Agrifood Technology (Werribee, Australia). In brief, protein content was determined using the Kjeldahl method [American Association of Cereal Chemists (AACC) Methods 70-20A and 70-70; starch and total free sugars (fructose, glucose, lactose, maltose, and sucrose) by in-house developed liquid chromatography—mass spectrometry (LC-MS); β-glucan using enzymatic method after hydrolysis by β-glucosidase (AOAC International Official Method 995.16 and AACC Method 32-23); and water soluble carbohydrates by water extraction and the anthrone method (AFIA 1.11R).

**Urea-SDS-PAGE and Western Blot Analysis**

One dimensional urea-sodium dodecyl sulfate polyacrylamide protein gels and Western blots were run as previously described (Supplementary Table S1) by Agrifood Technology (Werribee, Australia). Purified avenin was also screened for heavy metal contamination. The flour was extracted using food grade procedures and ethanol in a lab decontaminated to remove traces of wheat flour (Manildra Group, Nowra). All containers used for solvent storage and extraction were Food and Drug Approved and bisphenol A-free (Bunnings, Australia).

**Effect of Solvent Polarity on Small Scale Avenin Precipitation**

Oat flour (500 g) was extracted twice in 50% (v/v) ethanol (750 mL) and the extracts pooled. Duplicate 10 mL aliquots of the pooled 50% (v/v) ethanol extract containing 5.2 mg protein/mL was subject to varied total ethanol concentration by diluting the 50% (v/v) ethanol extract with either water, to achieve a final ethanol concentrations of 10–41% (v/v), or with ethanol to achieve final ethanol concentrations of 66–90% (v/v) (Figure 1A). In addition the 50% (v/v) ethanol extract was also chilled at 4°C and centrifuged as below (Figure 1A). Ethanol extracts were centrifuged at 3000 × g for 10 min at room temperature and pellets were dissolved in 8 M urea, 1% (w/v) dithiothreitol (DTT), 20 mM triethylamine-HCl (pH 6) (Urea/DTT) during overnight incubation at room temperature. The protein content of the resultant solutions was measured by Bradford, and 20 and 2 µg protein aliquots were subjected to Urea-SDS-PAGE and western blot respectively (Figures 1B,C).

**Chill Precipitation of a Range of Gluten Proteins**

Gluten proteins were isolated from wheat, barley and oat flour by extracting 5 g flour in 15 mL of 50% (v/v) ethanol, vortexing regularly over 1 h, and centrifuging at 3,000 g for 1 h. The 50% ethanol (v/v) supernatants were chilled at 4°C overnight, centrifuged as above and the pellets redissolved in Urea/DTT (wheat 10 mL, barley 10 mL, and oats 1 mL). The prolamin content of the chill precipitates were compared to duplicate extracts of 50 mg (wheat, barley) or 100 mg oats in 1 mL of 50% (v/v) propan-2-ol (IPA), 1% (w/v) DTT (IPA/DTT) which was extracted by violent reciprocal shaking in a Savant bead beater at 30 movements s⁻¹ for 1 min and centrifuged at 13,000 x g for 5 min. The protein content in the IPA/DTT supernatants and the chill-precipitated pellets were determined and either 20 or 2 µg protein were loaded on each lane of a protein gel and western blot, respectively (Figures 2A,B).

**Avenin Isolation From 500 g Oats**

Oat flour (500 g) was shaken regularly over 2 min, 90 min, or for one or 2 days in 750 mL of 50% (v/v) ethanol and then centrifuged at 500 g for 5 min and the supernatant reserved. Pellets were resuspended in 750 mL 50% (v/v) ethanol, re-centrifuged and the process repeated. The yield of protein was determined in the pooled supernatants (Figures S1A,B).
**Large Scale (Sequential) Oat Extraction**

Over the course of 9 days in January 2018 and May 2018, two lots of 200 kg of oat flour were ground in a blender to a fine flour, and extracted with 50% (v/v) ethanol as follows. First, 8 kg lots of oat flour were soaked in 12 L of 50% (v/v) ethanol overnight with occasional mixing at room temperature. Tap water was used for all solutions except where noted. In the morning, the oat flour suspension was stirred and decanted into successive 6 × 500 mL buckets and centrifuged at 800 × g for 5 min at 20°C in a Sigma 6-16S centrifuge to give a firm pellet. The clear supernatants were pooled in a 30 L bottle and chilled at 4°C for 1–2 days to selectively precipitate the avenins. The bulk of the avenin settled after 2 days storage at 4°C and was removed from the bottom of the storage container by decanting the supernatant. The avenin precipitate which remained in the supernatant was collected by centrifugation at 5,000x g for 10 min at 4°C and formed a clear honey-like pellet which, with the bulk of the avenin above, was resuspended in a minimum volume of 10% (v/v) ethanol, made with reagent grade 18 MΩ water, and stored at 4°C. Clumps of precipitated avenin were dispersed with an overhead blender, frozen, and freeze-dried in a dedicated gluten-free facility to yield a white powder which was stored dry at −20°C until required. A final yield of 0.9 and 1.2 kg of freeze dried avenin was recovered from each 200 kg oat flour (Figures S2A–C).

**Reversed Phase High Pressure Liquid Chromatography (RP-HPLC) Analysis**

Purified, freeze dried avenin (10 mg) was re-solubilized using 70% (v/v) ethanol and vortexed for 30 min (MO BIO Laboratories, Inc. Vortex-Genie® 2). Samples were prepared in triplicate and were centrifuged for 20 min at 15870x g in an Eppendorf Centrifuge 5424. The supernatant was filtered using a 0.45 μm filter. The protein extracts were separated using an Agilent 1200 LC system (Agilent Technologies) using a modified method (32). An aliquot (10 μl) of extract was injected into a C18 reversed-phase Zorbax 300SB-C18 column (4.6 × 150 mm, 5 μm, 300 Å, Agilent Technologies) maintained at 60°C. The eluents used were ultrapure water (solvent A) and acetonitrile (solvent B), each containing 0.1% trifluoroacetic acid (TFA) (HPLC grade, Sigma Aldrich). The separation was carried out using a linear gradient from 33 to 80% solvent B over 65 min at a flow rate of 1 mL/min.

**Protein Profiling Using Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) Analysis**

Mass spectra representing the protein composition of the prolamin-enriched fraction were obtained from both flour and the purified avenin, and the RP-HPLC fractions collected from the purified avenin sample using MALDI-TOF-MS. Briefly, 60 mg flour sample or 10 mg purified avenin was extracted in triplicate using 300 μL of 70% (v/v) ethanol with vortex mixing for 30 min at room temperature. The protein extract (200 μL) as well as the equivalent amount of eluent from each collected RP-HPLC peak were lyophilized and resuspended in matrix consisting of 40 mg of sinapinic acid (SA), 600 μL of acetonitrile, 360 μL of methanol and 80 μL of water. An aliquot (1 μL) of this matrix was spotted on a 100 spot MALDI-TOF plate and an additional 1 μL sample layer was applied. An Applied Biosystems Voyager DE Pro MALDI-TOF mass spectrometer was operated in linear high mass positive mode using 2050 V laser intensity, an
acceleration voltage of 25 kV, grid at 93% and guide wire at 0.2 settings, with 700 ns delay time. A total of 1,000 laser shots were averaged per spectra with three technical replicates analyzed. The detection mass range was set between m/z 10,000–60,000.

**LC-MS/MS Analysis of the Collected RP HPLC Peaks**

Protein samples were digested by chymotrypsin and peptides were extracted according to standard techniques (33). The peptide samples were analyzed by LC-MS on an Agilent 1260 Infinity HPLC system coupled to an Agilent 1260 Chipcube Nanospray interface on an Agilent 6540 mass spectrometer. Peptides were loaded onto a ProtID-Chip-150 C18 column (Agilent) and separated with a linear gradient of solvent A (2% acetonitrile/97.9% water/0.1% formic acid v/v/v) and solvent B (98% acetonitrile/1.9% water/0.1% formic acid v/v/v) from 2 to 98% solvent B over 18 min. Spectra were analyzed to identify proteins of interest using in silico proteolytic digests of Poales subset of UniProt-KB database (accessed 23/05/2019) supplemented with an oat seed transcriptome dataset (34) and appended with the common repository of adventitious proteins (cRAP). The number of protein sequences in the database was 861,955.

**Protein Identification From the Enriched Avenin and Oat Flour**

Proteins were extracted in four replicates using the finely ground oat cv Wandering flour and solvents suitable to obtain gluten protein enriched extracts: A − 50% (v/v) ethanol; B − 55% (v/v) IPA + 2% (w/v) DTT in water following the protocols of Colgrave et al. (31). The purified avenin sample was resolubilized in 50% (v/v) ethanol. From these, 100 µL aliquots of extract were applied to a 10 kDa molecular weight cut-off filter (Millipore, Sydney, Australia), alkylated using iodoacetamide and digested overnight using sequencing-grade trypsin (Promega, Madison, USA) or chymotrypsin (Promega, Madison, USA) as described in Fallahbaghery et al. (35). After digestion, samples were centrifuged at 20,000x g for 15 min and the digested filtrates were dried in a Speedvac (Thermo Fisher Scientific) and the obtained peptides were stored at −20°C until analysis.

Prior to LC-MS analysis the peptides were resuspended in 100 µL of 1% (v/v) formic acid. An aliquot (4 µL) of the peptide digest solutions were separated on an Eksigent NanoLC 415 system (SCIEX, Redwood City, USA) using a trap-elute configuration and 10 µL/min flow rate for trapping and 5 µL/min flow rate for separation. A Protocol C18 120Å trapping column (3 µm particle size, 10 mm × 300 µm, Trajan Scientific, Australia) and an
Eksigent ChromXP C18 120Å analytical column (3 μm particle size, 150 mm × 300 μm) was used with a linear gradient from 3 to 25% solvent B over 68 min. Mobile phases consisted of solvent A [0.1% (v/v) formic acid/5% (v/v) dimethyl sulfoxide/94.9% (v/v) water] and solvent B [0.1% (v/v) formic acid/5% (v/v) dimethyl sulfoxide/84.9% (v/v) acetonitrile/10% (v/v) water], and 0.1% (v/v) formic acid/99.9% (v/v) water was used to load the trap column. The eluate was directed into a TripleTOF 6600 MS (SCIEX), operating in operation independent acquisition mode over mass range m/z 100–200. The Paragon algorithm of ProteinPilot 5.0.2 Software (SCIEX) was used for protein identification (36). The tandem mass spectrometry data were searched against the in silico proteolytic digests of Poales subset of UniProt database (accessed 23/05/2019) supplemented with the oat seed transcriptome data (34) and appended with the common Repository of Adventitious Proteins (cRAP) database. The database search results were examined and identifications were confirmed if they passed a 1% global false discovery rate (FDR) threshold as determined by the built-in FDR tool within ProteinPilot software (37). The resulting protein dataset was analyzed to identify avenins using the representative prolamin characteristics as described (38). Pfam domains, cysteine residues and major known T cell epitopes (DQ2.5-ave-1a, 1b, 1c, and 2) were mapped to the identified protein sequences using CLC Genomics Workbench v12 (Qiagen, Aarhus Denmark). Protein sequences were aligned using ClustalW algorithm and phylogenetic analysis was performed as reported elsewhere (39).

RESULTS

Effect of Solvent Concentration on Avenin Precipitation

Many gluten proteins can be dissolved in 50% (v/v) ethanol or 2-propanol and precipitated by dilution with either water or alcohol. The polarity of the 50% (v/v) ethanol avenin extract was varied by diluting the 50% ethanol extract with water to achieve final concentrations of 10–41% ethanol (v/v), or with ethanol to achieve final concentrations of 66–90% ethanol (v/v) (Figure 1A). All additions (water or ethanol) to the 50% ethanol extract produced a milky white precipitate; however only those precipitates produced by increasing the ethanol addition could be conveniently precipitated. The cloudy precipitate produced by adding water was extremely difficult to spin down and resisted precipitation at 5,000 g, beyond the capacity of the centrifuge used for the large scale avenin preparation. Fortuitously, chilling the 50% ethanol extract at 4°C for 10 min was noted to selectively precipitate avenin, producing a milky white precipitate that could be precipitated at either 500 g or 3000 g over 10 min (Figure S1B) or that settled at 1 g overnight. The chill-induced precipitation of avenin commenced below 15°C and could be reversed by warming, resulting in a clear solution that could be reproduced at least 10 times. The purity of the precipitates produced by varying the ethanol concentration, or chilling, was investigated by comparing proteins (Figure 1B) corresponding with avenin bands on a western blot (Figure 1C). All of the major bands present in the protein gel (Figure 1B, 1–6) correspond to avenins identified in the western blot (Figure 1C, 1–6). Some non-avenin proteins were present in the protein gel (Figure 1B, *). In addition the intensity of both protein and western bands was a maximum in the chill precipitation from 50% ethanol (Figures 1B,C). This indicated that chill precipitation produced an avenin precipitate of high purity showing higher specificity for avenins.

Chilling the water-induced precipitates at 4°C did not help the suspensions to precipitate, possibly due to protein-lipid binding causing the avenins to float. Defatting the oat flour with common defatting solvents (i.e., butanol, ether, or hexane) was not possible due to food safety concerns. For instance, n-hexane biodegrades to form a neurotoxin that must be avoided to maintain food grade standard. Successful and complete defatting of oat flour with 100% ethanol has been reported (40). However, in this study ethanol defatting did not allow protein precipitation at lower centrifugal force, suggesting that the difficulty in pelleting the water-induced precipitates was not due to lipid interaction.

Chill Precipitation Is a General Method Applicable to a Range of Gluten Proteins

Chill-induced precipitation was assessed for its utility as a general method for isolating gluten proteins. Gluten proteins were isolated from oats, barley and wheat in 50% (v/v) ethanol extracts, followed by chill precipitation (Figures 2A,B, Chill ppted, Oats Chill Precipitated (OCP), Barley Chill Precipitated (BCP), Wheat Chill Precipitated (WCP), respectively), and compared to gluten proteins isolated by duplicate extraction of oats, barley and wheat in 50% (v/v) ethanol, 1% (w/v) DTT (Figures 2A,B, 50% ethanol/DTT, O, B, W, respectively). Previous studies have demonstrated that IPA/DTT is able to efficiently extract the majority of gluten proteins (35). In each case gluten proteins, numbered 1–28 in both images, and by definition extracted by 50% (v/v) ethanol, 1% (w/v) DTT were present in the corresponding 50% (v/v) ethanol chill-precipitated fractions. This was observed for Coomassie stained protein bands (Figure 2A) and gluten-specific proteins by western blot (Figure 2B, highlighted in Figures 2C,D) confirming that chill precipitation isolated the same range of gluten proteins that were isolated from wheat, barley, and oats as extraction in 50% (v/v) ethanol/1% (w/v) DTT, thus confirming the general nature of the chill precipitation method.

Avenin Yield and Purity

The maximum protein yield was produced by extracting 500 g oat flour in 750 mL of 50% (v/v) ethanol over 1–2 days (Figure S1A). The protein purity of the large scale avenin preparation was firstly examined by resolving protein bands with detection using a general protein stain (Coomassie Blue G250; Figure 3A). The protein bands were then compared to avenin bands identified by a general anti-gluten antibody on a Western blot (Figure 3B) for large scale avenin preparations 1 and 2 (Prep1 and Prep2). Using calibrated pre-stained standards on the blot and protein gel, avenin bands on both the protein gel and western blot were shown to be of the same molecular weight (Table 1). It is clear that the protein bands (Figure 3A) were due to the dominant avenin bands on the western blot (Figure 3B), except for one
Two hundred kilograms of oat flour was successively purified to yield two lots of purified avenin (Prep 1) and (Prep 2) are shown calibrated against pre-stained 10 kDa ladder (PM). Avenin was dissolved in 8 M urea, 1% DTT, 20 mM triethylamine (pH6), protein measured and 1, 2, 4, or 5 ug loaded per lane as shown. A single non-avenin protein band was present at 14.1 kDa (Figure 2A, white broken rectangle) corresponding to 4.2% of total band intensity. This does not correspond to an avenin band in the western blot 2B, and was probably due to α-amylase/trypsin inhibitors.

The protein purity was calculated from the percentage of the protein load attributed to avenin bands in the protein gel. The average purity of both preparations shown for the four 2 µg lanes on the protein gel was 95.8 ± 0.01%.

### Comparative Proteomic Analysis of the Enriched Avenin and Oat Flour

Previous studies have shown that gluten proteins can be efficiently extracted from gluten using alcohol in the presence of reducing agents. Such solvents are not applicable to production of food grade extracts, but are suitable for biochemical analyses that aim to identify the protein complement in grains, flours, and food products.

Extraction using IPA/DTT showed the highest number of proteins in the oat flour sample after LC-MS/MS analysis of the trypsin digested sample, with 276 proteins identified at the protein band at ~14 kDa, which did not correspond to an avenin band in the western blot (Figure 3A, marked by a broken white rectangle). Note that the 9 kDa prestained marker did not bind to the membrane and did not appear in the Western blot (Figure 3B, PM). The protein purity was calculated from the percentage of the protein load attributed to avenin bands in the protein gel. The average purity of both preparations shown for the four 2 µg lanes on the protein gel was 95.8 ± 0.01%.

### Proximate Composition Analysis

The protein content was assessed by the Kjeldahl method revealing 85.4% protein. The remainder of the preparation consisted of low concentrations of starch, β-glucan, free sugars and water soluble carbohydrates. The starch content was 1.8% on a dry weight (DW) basis. The β-glucan content was 0.2% DW, total free sugars were 1.8% DW and the total water-soluble carbohydrate (WSC) content was 4.6% DW. As starch is insoluble, it does not contribute to the WSC content. The total free sugars (at 1.8% DW) include fructose, glucose, lactose, maltose and sucrose, and are soluble and are thus included in the WSC measurement, leaving 2.8% DW attributed to other sugars, such as oligosaccharides, small fructans, and other complex sugars.

Food grade purity was confirmed by nil detection of herbicides and/or pesticides (Supplementary Table S1). No inadvertent chemical contamination was detected in either of the oat crops. Both oat crops were tested for the presence of aflatoxins (Supplementary Table S1), and all were below the limit of detection (LOD listed in Supplementary Table S1). The purified avenin was also tested for heavy metal contamination. Mercury, chromium and lead were all below the limit of detection. Copper was reported to be 5.1 and aluminum 58 mg/kg. These are within acceptable safety limits. The US Food and Drug Administration (FDA) reports that 10–100 mg aluminum per day is acceptable (41). The proposed feeding trial will involve a daily intake of 0.35 mg aluminum in a 6 g serve of avenin. The FDA does not define a limit on copper safety but these levels and much higher are common in other foods. The Food Standard Australia New Zealand code does not specify levels for copper or aluminum.
99% protein confidence level and additional 121 proteins were identified when the confidence level was lowered to 95%. It should be noted that LC-MS/MS is a very sensitive technique capable of detecting proteins that vary in abundance over four orders of magnitude. Detection of a number of non-avenin proteins does not imply reduced purity, but that the technique employed was capable of identifying a range of co-extracted proteins that were not obvious on the gel images (Figure 3). This protein set included 20 avenin sequences, 18 of which were identified with 99% confidence (Table 2). Additionally, there were 25 ATIs, 11 lipid transfer proteins (LTPs) and 15 vromindolines and grain softness proteins identified. A further 38 proteins were identified with the cupin-1 domain that is characteristic of globulins and germins expressed in seeds. The remaining 288 proteins represented a range of enzymes and metabolic proteins. The chymotryptic digested IPA/DTT extract revealed 136 proteins, of which 106 were detected with 99% protein confidence level. Within this set, 25 avenins (20 with 99% confidence level), 17 ATIs, 5 LTPs, 9 vromindolines and 26 globulins and germins were identified (Table 2). Comparing the trypsin and chymotryptic digests yielded 10 avenins, 14 ATIs, 7 vromindolines and 4 LTPs that were commonly identified when IPA/DTT extraction was used during the sample preparation.

Table 2 lists the number of proteins identified at 95% and 99% confidence levels in the flour and purified avenin samples. The number of identified proteins varied depending on the extraction method and the presence of co-extracted proteins. The total number of proteins identified in the flour sample was 186, with 33 at 95% confidence and 97 at 99% confidence. In the purified avenin sample, 97 proteins were identified at 95% confidence and 59 at 99% confidence.

### Table 2 | Number of detected protein types at 95 and 99% confidence levels.

| Protein type | Protein confidence | IPA/DTT | Flour | Purified sample |
|-------------|-------------------|---------|-------|----------------|
|             |                   | TR<sup>2</sup> | CTR<sup>2</sup> | TR | CTR |
| Avenin      | 99%               | 18      | 20    | 17  | 19  |
|             | 95%               | 20      | 25    | 18  | 20  |
| ATI         | 99%               | 18      | 17    | 15  | 16  |
|             | 95%               | 15      | 9     | 11  | 5   |
| Vromindoline| 99%               | 14      | 8     | 10  | 5   |
| and GSP    | 95%               | 15      | 9     | 11  | 5   |
| LTP and nsLTP | 99%             | 8       | 4     | 7   | 4   |
| Globulins   | 99%               | 11      | 5     | 9   | 4   |
| Enzymes and metabolic proteins | 99% | 32      | 24    | 12  | 8   |
| Total number of proteins | 95% | 288     | 54    | 152 | 48  |

<sup>1</sup>5% IPA + 2% DTT extraction buffer; <sup>2</sup>trypsin; <sup>3</sup>chymotrypsin.

Protein Molecular Weight and Hydrophobicity Distribution Within the Avenin-Enriched Extract

Altogether 25 protein peaks were identified in the unpurified extract using MALDI-TOF MS with centroid mass values ranging between 19.3 and 32.4 kDa (Figure 4). The proteins were grouped into three distinct groups: three proteins represented proteins below 22.4 kDa, eight proteins with centroid mass values between 22.4 and 24.4 kDa and 13 proteins with a centroid mass range of 25.8 and 32.4 kDa.

The purified protein sample was also separated based on hydrophobicity using RP-HPLC (Figure 5). The obtained chromatogram peaks were grouped into two retention time ranges. The first group represented peaks between retention time values of 27.0 and 31.3 min and accounted for ~57% of the total protein. In this subgroup peaks between 29.6
and 31.3 min represented the most abundant peaks. The second subgroup that accounted for 43% of the total protein content was composed of 13 peaks and retention time values ranged between 37.6 and 46.0 min. Peaks with retention time values of 41.1, 46.0, and 45.1 min were the most abundant. Based on the obtained chromatogram there were 18 peaks collected and the undigested samples were subjected to protein profiling using MALDI-TOF MS. In parallel to this analysis proteins present in the chymotrypsin-digested RP-HPLC peaks were identified using LC-MS/MS after chymotrypsin digestion.

The RP-HPLC peaks were also quantified by calculating the mean Area (mAU * s) values of the three replicates × three injections. The absolute amount of protein within each peak was estimated based on the obtained protein content using the Kjeldahl method as described in section Proximate Composition Analysis. The quantitative results, including retention time ranges, calculated mean values as absolute amounts of protein/100 g purified protein are provided in Table 3.

The RP-HPLC peaks RP3-RP7 comprised proteins with the larger molecular mass range (above 26 kDa). Peaks RP1 and
RP8 were comprised of proteins spanning the entire mass range while peaks RP9-RP12 mainly included proteins with smaller molecular mass values (below 22.5 kDa). Peaks RP15-RP18 comprised proteins between 22.5 and 24 kDa and above 26 kDa. The number of representative avenin protein types per peak is shown in Table 4. Proteins present in the 18 peaks consisted of avenins and gliadin-like avenins, however peptides characteristic of ATIs were also confidently detected in peak RP2 (Table 4). RP-HPLC analysis indicated that the proteins that eluted between 26.9 and 31.2 min exclusively contained proteins with the DQ2.5-ave-1a epitope and this fraction represented approximately 55.9 g in 100 g purified protein. While DQ2.5 ave-1b epitope containing proteins were detected in the retention time range of 38.5–45.9 min, proteins with DQ2.5-ave-2 epitope were only detected in the RP peak 11.

Characterization of the Identified Avenin Types

As the purpose of the avenin feeding trials is to provoke a T cell response to assess the clinical significance of oats in CD, it was important for us to confirm the presence of the previously reported and potentially pathogenic avenin peptides that encompass T cell epitopes (13). Avenin protein sequences that were detected in any of the analyzed samples were used for phylogenetic analysis and epitope mapping. The identity of the known T cell epitopes and the protein identification analyses of oat flour and purified avenin samples along with RP peak analysis were used to annotate the phylogenetic tree and compare the characteristics of the sequence groups. The sequences were grouped into major clusters according to the presence of conserved avenin-specific T cell epitopes (Figure 6, Supplementary Table S2). Group 1 included proteins with the epitope DQ2.5-ave-1b, the majority of the group 2 sequences contained DQ2.5-ave-1c, group 3, the largest group, was typified by the presence of DQ2.5-ave-1a and group 4 was typified by the presence of DQ2.5-ave-2. The sub-branch without T cell epitopes (group 5) represents protein sequences mostly similar to high and low molecular weight glutenin-like sequences. The results clearly indicate that the 50% ethanol extraction method is suitable to extract the major epitope containing avenin types. The resultant purified protein contains all of the reported immunogenic avenin peptides, and therefore should be suitable as a way to assess their clinical toxicity in feeding studies.

**DISCUSSION**

Determining if oats should be excluded or included in the GFD is an important issue with medical and societal implications. Dedicated, controlled feeding studies are needed to definitely resolve this issue. Here, we demonstrate an approach that enables the production of a highly purified oat avenin preparation, containing all the known immunogenic avenin T cell epitopes, which contains minimal levels of other carbohydrates or proteins which could otherwise confound the interpretation of the feeding trial. This avenin preparation will facilitate immune and feeding studies to test the suitability of oats in CD. Studies can now be undertaken to assess the immunogenicity of this protein using patient-derived gluten-specific T cells, and employ feeding studies in patients with CD to determine its biological effects.

Despite the many nutritional benefits of oats, contradictory clinical feeding studies, and lack of a clear scientific rationale for dietary guidelines have led to differing views on the safety of oats consumption in CD. A systematic review on studies of oat safety in CD (i) identified several limitations including (i) small sample sizes: uncommon patients with oats sensitivity may not have been included; (ii) assessment of GFD adherence: often not reported; (iii) adverse symptoms: cannot determine if they are related to oats avenin or the fiber load of oats itself; and (iv) oat cultivars: usually not reported. Furthermore, study withdrawals which were often due to adverse gastrointestinal symptoms and/or the inability to maintain the oats diet, may have underestimated the adverse impact of oats intake, and recruitment bias, may lead to oats-sensitive patients avoiding participating in oats feeding studies. The authors concluded: “Our confidence is limited by the low quality and limited geographic distribution of the data” and “Rigorous double-blind, placebo-controlled, randomized controlled trials, using commonly available oats sourced from different regions, are needed.” (4).

An important consideration is that testing for cereal contamination over the last two decades has highlighted a high frequency of commercial oats brands contaminated by wheat, barley and/or rye prolamin in amounts toxic to CD patients (43–45). Contamination can occur since wheat, barley, and oats are grown in the same areas and often harvested and transported with the same machinery. The presence of a single grain of wheat in 200 g of oats can result in the wheat gluten level of >100 ppm; well above the 20 ppm level set in most legislations as the upper
**TABLE 4** | Protein characterization of the identified RP-HPLC peaks.

| Fraction # | No. MS peaks in HPLC fraction* | Observed mass range (m/z) | Most intense peaks in MALDI profile | Accession (UniProt/ transcript ID)* | Confidence level | Monoisotopic mass (signal peptide removed) | Epitope |
|------------|---------------------------------|---------------------------|-------------------------------------|-------------------------------------|-----------------|------------------------------------------|---------|
| 1          | 15                              | 20543–28907               | 28604                               | LOL6J0                             | 99%             | 30789                                    | DQ2.5-ave-1a |
|            |                                 |                           | 27783                               | Asat-prolamin54                     | 99%             | 23496                                    | DQ2.5-ave-1a |
| 2          | 11                              | 21321–28711               | 27760                               | LOL6J0                             | 99%             | 30789                                    | DQ2.5-ave-1a |
|            |                                 |                           | 21321                               | LOL6K1                             | 95%             | 22031                                    | DQ2.5-ave-1a |
| 3          | 9                               | 21327–28652               | 28467                               | LOL6J0                             | 99%             | 30789                                    | DQ2.5-ave-1a |
| 4          | 6                               | 22038–28675               | 28498                               | Asat-prolamin2 Q09072              | 99%             | 25189                                    | DQ2.5-ave-1a |
| 5          | 5                               | 22049–28704               | 28486                               | Asat-Prolamin10 LOL6K1             | 99%             | 22031                                    | DQ2.5-ave-1a |
| 6          | 4                               | 27609–28659               | 28478                               | Asat-Prolamin10 LOL6K1             | 99%             | 22031                                    | DQ2.5-ave-1a |
| 7          | 4                               | 22009–28481               | 27595                               | LOL6J0                             | 99%             | 30789                                    | DQ2.5-ave-1a |
| 8          | 10                              | 21240–28516               | 24184                               | Asat-Prolamin10 Q09072             | 99%             | 23539                                    | DQ2.5-ave-1a |
| 9          | 2                               | 22513–22711               | 22513                               | LOL4J7                             | 99%             | 22481                                    | DQ2.5-ave-1c |
| 10         | 4                               | 21893–25833               | 22465                               | LOL4J7                             | 99%             | 22481                                    | DQ2.5-ave-1c |
|            |                                 |                           | LOL6J0                             | 99%                                 | 30789           | DQ2.5-ave-1a                             |         |
| 11         | 2                               | 21792–22495               | 22495                               | LOL4J7                             | 99%             | 22481                                    | DQ2.5-ave-1c |
|            |                                 |                           | Q09072                             | 99%                                 | 23539           | DQ2.5-ave-1a                             |         |
|            |                                 |                           | IEPE88                             | 99%                                 | 25862           | DQ2.5-ave-1b                             |         |
|            |                                 |                           | IEPE86                             | 95%                                 | 21915           | DQ2.5-ave-2                              |         |
|            |                                 |                           | LOL6J0                             | 95%                                 | 30789           | DQ2.5-ave-1a                             |         |
| 12         | 3                               | 22495–22703               | 22495                               | LOL4J7                             | 99%             | 22481                                    | DQ2.5-ave-1c |
|            |                                 |                           | 22598                               | IEPE58                             | 95%             | 27966                                    | DQ2.5-ave-1b |
| 13         | 5                               | 22481–25855               | 22481                               | LOL4J7                             | 99%             | 22481                                    | DQ2.5-ave-1c |
|            |                                 |                           | Asat-Prolamin71 LOL6J0             | 99%                                 | 22752           | DQ2.5-ave-1b                             |         |
|            |                                 |                           | 95%                                 | 30789                              | DQ2.5-ave-1a    |                                         |         |
| 14         | 5                               | 22474–26051               | 25850                               | IEPE58                             | 99%             | 27966                                    | DQ2.5-ave-1b |
| 15         | 11                              | 22642–27149               | 25853                               | Asat-Prolamin71 Q8ZCU7 Q09079      | 99%             | 21628                                    | DQ2.5-ave-1c |
|            |                                 |                           | 23314                               |                                     | 99%             | Fragment                                  |         |
| 16         | 7                               | 23317–27187               | 23735                               | IEPE54                             | 99%             | 26895                                    | DQ2.5-ave-1b |
|            |                                 |                           | LOL6J0                             | 99%                                 | 30789           | DQ2.5-ave-1a                             |         |
|            |                                 |                           | Asat-Prolamin15                    | 95%                                 | 20556           | DQ2.5-ave-1c                             |         |
| 17         | 10                              | 23317–27328               | 23729                               | IEPE58                             | 99%             | 27966                                    | DQ2.5-ave-1b |
|            |                                 |                           | Asat-Prolamin15                    | 99%                                 | 20556           | DQ2.5-ave-1c                             |         |
| 18         | 8                               | 23294–27363               | 23294                               | IEPE57                             | 99%             | 27948                                    | DQ2.5-ave-1b |
|            |                                 |                           | 26370                               |                                     |                 |                                         |         |

*Peaks above 10% intensity in MALDI-TOF MS were considered.

Limit for gluten-free food status. Failure to provide harvesting, transport and milling facilities dedicated to oats may easily result in significant inadvertent contamination by wheat grains.

Another challenge with oat feeding studies may arise from supplying insufficient avenin to provoke a measurable response in people with CD. With a short-term oral oat challenge of 100 g daily, 8% of patients with CD had pro-inflammatory T cell responses detectable in the bloodstream (13) in contrast to the 75–80% that would be seen after just four slices of wheat bread daily (46). To fully assess the clinical safety of oats we argue it will be important to deliver oats avenin at a “dose” sufficient to trigger both immune and biologic responses. While immune studies suggest oats avenin contain immunogenic sequences capable of stimulating gluten-specific T cells in CD, such a study may help
establish a safe threshold dose of oats for consumption in CD by correlating these findings with clinically important endpoints.

Here, we demonstrate that it is possible to produce 85% pure oat grain storage protein extracts from oat flour using repeated 8 kg scale avenin-enriched extractions. The IPA/DTT method combined with trypsin digestion yields a large number of gluten proteins from cereal grains such as wheat (31). This analysis in oats demonstrated that using 50% (v/v) ethanol was sufficient to identify a majority of the avenin protein types. The least represented group was that of proteins with the DQ2.5-ave-1b epitope. This protein type however, was extracted in higher number using the IPA/DTT solvent. Similarly, when reducing agent was added during the purified avenin resolubilization the protein group was better represented (data not shown). This indicates that these proteins with 9 cysteine residues in their sequence might be part of the protein polymer and therefore less soluble in the absence of reducing agent (Supplementary Table S2).

The final avenin preparation contains the avenin bands present in the initial crude 50% (v/v) ethanol extract. Thus, the majority of avenins are recovered by this process. Ninety six percent of the protein in the final protein preparation was due to authentic avenins which were identified by western blotting. The content of starch, β-glucan, sugars, and fatty acids were low.
in the final avenin preparation. Using repeated extractions it is possible to process 200 kg of oat flour in 9 days to produce ~1 kg of food-grade, avenin-enriched freeze-dried powder.

The RP-HPLC peak analysis indicated the presence of ATIs in the purified sample and this was verified with the comparative analysis using various extraction methods. The number of ATIs detected in the 50% (v/v) ethanol purified protein was in the same range as the avenins. Western blots show the presence of ATI is <4.2% however the precise amount requires further analysis. Other prolamin proteins were also detected. The number of LTPs and kernel structure-related vromindolines was in the same range as of the avenins. Furthermore, globulins, enzymes, and metabolic proteins were also present in large number. Comparison of the IPA/DTT extracted flour sample and the protein preparate clearly shows the depletion of other protein types in the protein preparate and the increase of detected avenin sequences. Using RP-HPLC analysis combined with the MALDI-TOF MS and LC-MS confirmed the presence of significant amount of avenins in the sample. RP-HPLC peaks 5, 6, 8 altogether represent about 40% of the measured protein amount. These peaks were primarily enriched in DQ2.5-ave-1a containing avenins.

Although CD is not a food allergy, controlling for potential confounding effects from ATIs or LTPs in the subsequent analysis of the avenin preparation will be important as these proteins have been associated with human disease including food allergies and Baker’s asthma. ATIs have also been implicated in in vitro studies to contribute to intestinal inflammation via activation of innate immune pathways (47, 48). Utilizing readouts specific to CD and gluten such as gluten-specific T cells will ensure assessment is focussed on biological effects driven by the avenin and not other components.

The public databases are relatively poor in oat specific storage protein sequences, therefore wild relatives of Avenae were also included in the analysis. In total, 185 avenin or avenin-like gliadin sequences were included in the data background. Due to this poor avenin protein sequence representation a precise protein identification is rather challenging but our results clearly indicated that the purified protein is enriched in avenin and gliadin-like proteins. Importantly, using an expanded prolamin database that also includes prolamin sequences of other Poales species, including wheat and barley, we have excluded the possibility of wheat and barley contamination in the oat purified protein.

Comparison of the MALDI-TOF and MicroLC-TripleTOF MS analysis results also revealed that, similar to wheat gliadins, the avenins show a significant level of genetic variability, indicating the presence of multiple gene copies with largely similar protein size and hydrophobicity within the used cultivar. It also indicates the possible presence of avenin alleles with slightly different protein mass values in the different Avena sativa cultivars and Avena species. Some of the protein peaks were present in multiple adjacent RP-HPLC peaks which might be due to the resolution limitations of RP-HPLC. Mass differences <100 Da observed in adjacent RP peaks can be explained by the presence of post-translational modifications and highly similar sequences with amino acid substitutions or insertions/deletions. Although the overlapping protein set between the different extraction protocols and the RP HPLC peak analysis was small, the avenin sequence analysis confirmed that proteins from the same avenin sub-types were detected. The background database used included <200 avenin sequences representing a rather narrow genetic variability of only a few Avena species and Avena sativa cultivars. The avenin sequences within the analysis set share 70–99% sequence identity within the groups and 24–45% sequence identity between the groups. Only a few avenin proteins were identified with nearly complete peptide coverage. This also demonstrates that the avenin sequences present in the cultivar Wandering are different from those in the public databases.

CONCLUSION

Resolving the issue of oat safety in people with CD will require feeding studies to assess the clinical and immune effects of pure oat avenin. The purity of oat avenin can be confirmed by rigorous proteomic characterization to control for confounding factors such as contamination or potential cross reactivity. A requirement for purified oat avenin for feeding studies was identified as far back as the 1950’s, but until recently, production of this at a scale and purity suitable for human feeding studies was not possible. With the method reported here, it is possible for the first time to generate highly pure avenin suitable for controlled feedings studies in CD. This will allow the biological effects of oats avenin to be assessed devoid of the confounding effects from other oat proteins, sugars or fiber, or non-oat sources of gluten. We believe this is a crucial advance that will allow this issue to be definitively assessed and resolved.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the manuscript/Supplementary Files.

AUTHOR CONTRIBUTIONS

JT-D conceived the study. The method was developed by GT and FB. The large-scale purification was completed by GT and FB. Protein analysis was completed by GT. RP-HPLC and MALDI-TOF analysis was carried out by CF and quantitatively evaluated by FB. Manuscript analysis and proteomic data analysis was carried out by AJ, MN-W, and MC. Bioinformatic analysis was completed by AJ. Proximate analysis was supervised by AR. MH contributed to study design and epitope analysis. All authors contributed to the writing of the manuscript.

FUNDING

JT-D was supported by the Mathison Centenary Fellowship (University of Melbourne). The Tye-Din Coeliac Research Lab are grateful for research support provided by Coeliac Australia and Coeliac UK.
ACKNOWLEDGMENTS

This work would not have been possible without the generous support of key individuals and businesses. Avenin was purified from wheat-free oats (cv Wandering), harvested in Sep 2016 and Dec 2017 by Kim and Danielle Rintoul in Williams, Western Australia. The oats were ground in a gluten-free, food-grade plant at Ward Mackenzie at Altona (Victoria), with the assistance of Sam Crispin. The avenin purification was carried out in food grade laboratories of the Manildra Group (Nowra, NSW) with the kind assistance of Amy Barrie and Mark Basinski.

REFERENCES

1. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. (2018) 16:823–6. doi: 10.1016/j.cgh.2017.09.016
2. Hardy MY, Tye-Din JA. Coeliac disease: a unique model for investigating broken tolerance in autoimmunity. Clin Transl Immunol. (2016) 5:e112. doi: 10.1038/cti.2016.58
3. Dicke WK, Weijers HA, Van De Kamer JH. Coeliac disease. II: the presence in weath of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr. (1953) 42:34–42. doi: 10.1111/j.1651-2227.1953.tb05563.x
4. Pinto-Sanchez MI, Causada-Calo N, Bercik P, Ford AC, Murray JA, et al. Safety of adding oats to a gluten-free diet for patients with celiac disease: systematic review and meta-analysis of clinical and observational studies. Gut Physiology. (2017) 153:395–409 e395. doi: 10.1033/gastro.2017.04009
5. Sjoberg V, Hollen E, Pietz G, Magnusson KE, Sundstrom M, et al. Noncontaminated dietary oats may hamper normalization of the intestinal immune status in childhood celiac disease. Clin Transl Gastroenterol. (2014) 5:e58. doi: 10.1038/cti.2014.9
6. Peraaho M, Kaukinen K, Mustalathi K, Vuolleenaho N, Maki M, Laipala P, et al. Effect of oats containing gluten-free diet on symptoms and quality of life in coeliac disease. A Randomized Study Scandinavian. J Gastroenterol. (2004) 39:27–31. doi: 10.1080/00365520310007785
7. Tuire I, Katri H, Jukka P, Paivi S, et al. Persistent duodenal intraepithelial lymphocytosis despite a long-term strict gluten-free diet in celiac disease. Am J Gastroenterol. (2012) 107:1563–9. doi: 10.1038/ajg.2012.220
8. Lundin KE, Nilsen EM, Scott HG, Loberg EM, Gjoen A, Bratlie J, et al. Oats induced villous atrophy in coeliac disease. Gut. (2003) 52:1649–52. doi: 10.1136/gut.52.11.1649
9. Silano M, Di Benedetto R, Maialleti F, Verzichelli A, Calcatera R, Cornell HJ, et al. Avenins from different cultivars of oats elicit response by coeliac peripheral lymphocytes. Scand J Gastroenterol. (2007) 42:1430–2. doi: 10.1080/00365520701420750
10. Comino I, Rea A, Lorenzo L, Correlli L, Lopez-Casado MA, Barro F, et al. Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease. Gut. (2011) 60:915–22. doi: 10.1136/gut.2010.205268
11. Comino I, Bernardo D, Bancel E, De Lourdes Moreno M, Sanchez B, Barro F, et al. Identification and molecular characterization of oat peptides implicated on coeliac immune response. Food Nutr Res. (2016) 60:30324. doi: 10.3402/fnr.v60.30324
12. Arentz-Hansen H, Fleckenstein B, Mollberg O, Scott H, Koning F, Jung G, et al. The molecular basis for oat tolerance in patients with celiac disease. PLoS Med. (2004) 1:e1. doi: 10.1371/journal.pmed.0010001
13. Hardy MY, Tye-Din JA, Stewart JA, Schmitz F, Duduk NJ, Hanchapola I, et al. Ingestion of oats and barley in patients with celiac disease mobilizes cross-reactive T cells activated by avenin peptides and immuno-dominant hordein peptides. J Autoimmun. (2015) 56-56–65. doi: 10.1016/j.jaut.2014.10.003
14. Tye-Din JA, Stewart JA, Dromey JA, Beisbarth T, van Heel DA, Tatham A, et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med. (2010) 2:1–14. doi: 10.1126/scitranslmed.3001012
15. Food and Agriculture Organization. Oats Production in 2016, Crops/World Regions/Production Quantity from Pick Lists. Rome: FAOSTAT (2017).
16. Schalk K, Lexhaller B, Koehler P, Scherf KA. Isolation and characterization of gluten protein types from wheat, rye, barley and oats for use as reference materials. PLoS ONE. (2017) 12:e0172819. doi: 10.1371/journal.pone.0172819
17. Leffler D, Schuppan D, Pali-Schumann M, Najarian R, Goldsmith JD, Hansen J, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut. (2013) 62:996–1004. doi: 10.1136/gutjnl-2012-302196
18. Metzger M-H, Heier M, Maki M, Bravi E, Schneider A, Lowel H, et al. Mortality excess in individuals with elevated iga anti-transglutaminase antibodies: the KORA/MONICA Augsburg Cohort Study 1989–1998. Eur J Epidemiol. (2006) 21:359–65. doi: 10.1007/s10654-006-9002-4
19. Tatham A, et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med. (2018) 10:1–20. doi: 10.1126/scitranslmed.aao7227
20. Dennis M, Lee AR, McCarthy T. Nutritional considerations of the gluten-free diet. Gastroenterol Clin North Am. (2019) 48:53–72. doi: 10.1016/j.gtc.2018.09.002
21. Whitehead A, Beck EJ, Tosh S, Wolever TM. Cholesterol-lowering effects of oat beta-glucan: a meta-analysis of randomized controlled trials. Am J Clin Nutr. (2014) 100:1413–21. doi: 10.3945/ajcn.114.068108
22. Rasaie P, Jha A, Sabikki L, Kumar A, Unnikrishnan VS. Nutritional advantages of oats and opportunities for its processing as value added foods - a review. J Food Sci Technol. (2015) 52:662–75. doi: 10.1007/s13197-013-1072-1
23. Aaltonen K, Laurikka P, Huhtala H, Maki M, Kaukinen K, Kurppa K. The long-term consumption of oats in celiac disease patients is safe: a large cross-sectional study. Nutrients. (2017) 9:611. doi: 10.3390/nu9060611
24. Khan A, Suarez MG, Murray JA. Non-celiac wheat/gluten sensitivity. Clin Gastroenterol Hepatol. (in press). doi: 10.1016/j.cgh.2019.04.009
25. Skodje GL, Sarra VK, Minelle HJ, Rolfsen KI, Muir JG, Gibson PR, et al. Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity. Gastroenterology. (2018) 154:529–39 e522. doi: 10.1053/j.gastro.2017.10.040
26. Varney J, Barnett JA, Scarletta K, Catsos P, Gibson PR, Muir JG. FODMAPs: food composition, defining cutoff values and international application. J Gastroenterol Hepatol. (2017) 32:53–61. doi: 10.1111/jgh.13698
27. Moulton AL. The place of oats in the coeliac diet. Arch Dis Childhood. (1959) 34:51–5. doi: 10.1136/adc.34.172.51
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dye binding. Anal Chem. (1959) 37:768–76. doi: 10.1021/ac6003400
29. Colgrave ML, Goswami H, Byrne K, Blundell M, Howitt CA, Tanner GJ. Proteomic profiling of 16 cereal grains and the application of targeted
proteomics to detect wheat contamination. J Prot Res. (2015) 14:2659–68. doi: 10.1021/acs.jprot.5b00187
32. Larroque OR, Bekes F, Wrigley CW, Rathmell WG. Analysis of gluten proteins and flour blends by RP-HPLC. In: Shewry PR, Tatham AR, editors. Seventh International Workshop on Gluten Proteins. Bristol: Institute for Arable Crops Research (2000). p. 136–139. doi: 10.1039/978147552372-00136
33. Bringans S, Eriksen S, Kendrick T, Gopalakrishnakone P, Livk A, Lock R, Lipscombe R. Proteomic analysis of the venom of Heterometrus longimanus (Asian black scorpion). Proteomics. (2008) 8:1081–96. doi: 10.1002/pmic.200700948
34. Gutierrez-Gonzalez JJ, Tu ZJ, Garvin DF. Analysis and annotation of the hexaploid oat seed transcriptome. BMC Genomics. (2013) 14:471. doi: 10.1186/1471-2164-14-471
35. Fallahbaghery A, Zou W, Byrne K, Howitt CA, Colgrave ML. Comparison of gluten extraction protocols assessed by LC-MS/MS analysis. J Agric Food Chem. (2017) 65:2857–66. doi: 10.1021/acs.jafc.7b00063
36. Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics. (2007) 6:1638–55. doi: 10.1074/mcp.T600050-MCP200
37. Tang WH, Shilov IV, Seymour SL. Nonlinear fitting method for determining local false discovery rates from decoy database searches. J Proteome Res. (2008) 7:3661–7. doi: 10.1021/pr070492f
38. Juhász A, Belova T, Florides C, Maulis C, Fischer I, Gell G, et al. Genome mapping of seed borne allergens and immune-responsive proteins in wheat. Sci Adv. (2018) 4:eaar8602. doi: 10.1126/sciadv.eaar8602
39. Iwgsc. Shifting the limits in wheat research and breeding using a fully annotated reference genome. Science. (2018) 361:eaar7191. doi: 10.1126/science.aar7191
40. Zhou M, Robards K, Glennie-Holmes M, Helliwell S. Analysis of volatile compounds and their contribution to flavor in cereals. J Agric Food Chem. (1999) 47:3941–53. doi: 10.1021/jf990428l
41. Colgrave ML, Byrne K, Blundell M, Heidelerberger S, Lane CS, Tanner GI, et al. Comparing Multiple reaction monitoring and sequential window acquisition of all theoretical mass spectra for the relative quantification of barley gluten in selectively bred barley lines. Anal Chem. (2016) 88:9127–35. doi: 10.1021/acs.analchem.6b02108
42. Colgrave ML, Byrne K, Blundell M, Heidelerberger S, Lane CS, Tanner GI, et al. Preparation and Characterization of Avenin-Enriched Oat Protein gluten proteins in grain and flour blends by RP-HPLC. In: Shewry PR, Tatham AR, editors. Seventh International Workshop on Gluten Proteins. Bristol: Institute for Arable Crops Research (2000). p. 136–139. doi: 10.1039/978147552372-00136
43. Thompson T. Gluten contamination of commercial oat products in the United States. N Engl J Med. (2004) 351:2011–2. doi: 10.1056/NEJM200411043511924
44. Hernando A, Mujico JR, Mena MC, Lombardia M, Mendez E. Measurement of wheat gluten and barley hordeins in contaminated oats from Europe, the United States and Canada by Sandwich R5 ELISA. Eur J Gastroenterol Hepatol. (2008) 20:545–54. doi: 10.1097/MEG.0b013e3282f6597
45. Koerner TB, Cleroux C, Poirier C, Cantin I, Alimkulov A, Elamparo H. Gluten contamination in the Canadian commercial oat supply. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. (2011) 28:705–10. doi: 10.1080/19440049.2011.579626
46. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AVS. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med. (2000) 6:337–42. doi: 10.1038/73200
47. Junker Y, Zeissig S, Kim S-J, Barisani D, Wieser H, Leffler DA, et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med. (2012) 209:2395–408. doi: 10.1084/jem.20102660
48. Zevallos VF, Raker V, Tenzer S, Jimenez-Calvente C, Ashfaq-Khan M, Russel N, et al. Nutritional wheat amylase-trypsin inhibitors promote intestinal inflammation via activation of myeloid cells. Gastroenterology. (2017) 152:1100. doi: 10.1053/j.gastro.2016.12.006

Conflict of Interest: GT and JT-D are co-authors on a patent to use chill precipitation for gluten isolation (Provisional Patent Application no. 16/291,326) and Australia (Patent Application No. 2019204165). JT-D and MH are co-inventors of patents pertaining to the use of gluten peptides in therapeutics, diagnostics, and non-toxic gluten in celiac disease. JT-D holds shares in Nexppep Pty, Ltd. and is on the Scientific Advisory Board of ImmusanT, Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Tanner, Juhász, Florides, Nye- Wood, Békés, Colgrave, Russell, Hardy and Tye-Din. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Tanner, G; Juhász, A; Florides, CG; Nye-Wood, M; Békés, F; Colgrave, ML; Russell, AK; Hardy, MY; Tye-Din, JA

Title:
Preparation and Characterization of Avenin-Enriched Oat Protein by Chill Precipitation for Feeding Trials in Celiac Disease.

Date:
2019

Citation:
Tanner, G., Juhász, A., Florides, C. G., Nye-Wood, M., Békés, F., Colgrave, M. L., Russell, A. K., Hardy, M. Y. & Tye-Din, J. A. (2019). Preparation and Characterization of Avenin-Enriched Oat Protein by Chill Precipitation for Feeding Trials in Celiac Disease.. Frontiers in Nutrition, 6, pp.162-162. https://doi.org/10.3389/fnut.2019.00162.

Persistent Link:
http://hdl.handle.net/11343/245221

File Description:
published version

License:
CC BY